23/08/2025
Newer FDA approved Treatment for Alzheimer's Disease
*Anti-Amyloid Treatments*
These newest treatments to fight Alzheimer’s disease are immunotherapies targeting toxic amyloid-beta proteins that form plaques in the brain, a defining feature of the disease. Removing amyloid-beta from the brain reduces cognitive and functional decline in people living with early Alzheimer’s. Talk with your clinician about the risks and side effects associated with drugs in this class.
**KisunlaTM* (donanemab-azbt)*
FDA status: Approved in 2024.*
How it works: Kisunla is a type of amyloid immunotherapy drug* which targets a plaque-specific form of amyloid that is highly toxic and increases amyloid aggregation. In a phase 3 clinical trial, it slowed the progression of cognitive and functional decline by 35% in participants with early signs of Alzheimer’s disease, with 76.4% of participants showing amyloid clearing with PET imaging.
Delivery method: Administered intravenously (through a vein); in clinical trials, treatment was administered *every four weeks for up to 72 weeks.*
Side effects: In the phase 3 trial, common side effects included amyloid-related imaging abnormalities (ARIA), headache, and infusion-related reactions.
